Semaglutide Dose for Weight Loss: Complete Dosing Guide
Semaglutide dosing depends on the product, formulation, indication and treatment response. This guide focuses on weekly injections for weight management, explains the familiar escalation steps, and separates trial outcomes from expectations for an individual month.
What Is Semaglutide?
Semaglutide is a GLP-1 receptor agonist. Oral and injectable products have different instructions; their milligram amounts are not interchangeable. Wegovy prescribing information
Evidence for weight loss comes from defined treatment programs. In STEP 1, 1,961 adults with overweight or obesity without diabetes received semaglutide 2.4 mg or placebo alongside lifestyle intervention for 68 weeks. Average weight change was −14.9% versus −2.4%. Those are group averages over the study, not a prediction for each patient. STEP 1 study
Standard Semaglutide Dosing Schedule
This is Wegovy injection escalation. Intolerance can delay increases; maintenance depends on indication and response. Wegovy prescribing information
| Week | Dose | Phase |
|---|---|---|
| Weeks 1-4 | 0.25mg once weekly | Initiation |
| Weeks 5-8 | 0.5mg once weekly | Escalation 1 |
| Weeks 9-12 | 1.0mg once weekly | Escalation 2 |
| Weeks 13-16 | 1.7mg once weekly | Escalation 3 |
| Weeks 17+ | 1.7mg or 2.4mg once weekly | Adult weight-loss maintenance; 2.4mg recommended |
The adult 7.2 mg option requires at least four weeks tolerating 2.4 mg and a clinical need for additional weight reduction—not an automatic next step. Wegovy prescribing information
Week 1-4: The 0.25mg Starting Dose
The first step is intended for initiation, not a test of your eventual maximum response. Keep a record of the supplied product, injection dates, symptoms and questions for your next visit.
Early experiences differ. An individual report of immediate appetite change may be genuine, but it does not establish how quickly everyone will respond or how many pounds they will lose in the first month. The STEP 1 outcome was measured over 68 weeks, not as a guaranteed result at each dose. STEP 1 study
Escalation Phase: Weeks 5-12
The dose steps organize treatment; they are not separate monthly weight-loss promises. Review tolerability before each planned increase.
Weeks 5-8: The 0.5mg Dose
Gastrointestinal symptoms may occur during escalation. A pooled analysis of STEP 1–3 found that most gastrointestinal events were mild-to-moderate and transient, but some participants discontinued treatment. It does not establish that symptoms resolve within a few days after every increase. Pooled STEP gastrointestinal analysis
Weeks 9-12: The 1.0mg Dose
One milligram was an active comparator in STEP 2, which studied adults with type 2 diabetes and overweight or obesity. That research does not make it a universally appropriate Wegovy maintenance dose or prove that it delivers the medication's full appetite effect. Different populations and treatment goals need separate interpretation. STEP 2 study
Final Escalation: Weeks 13-16
At 1.7 mg, do not assume earlier adaptation means side effects must now be minimal. The pooled STEP analysis found gastrointestinal events were more common during or shortly after escalation. Pooled STEP gastrointestinal analysis
Discuss both treatment response and your ability to eat and drink adequately. A calendar milestone alone is not a reason to push through troublesome symptoms.
Maintenance: 2.4mg Ongoing
Longer-term results can be substantial. STEP 5 randomized 304 adults without diabetes to semaglutide 2.4 mg or placebo plus behavioral intervention. At 104 weeks, average weight change was −15.2% versus −2.6%. Gastrointestinal events were reported by 82.2% versus 53.9%, mostly mild-to-moderate. STEP 5 study
These findings support sustained benefit during treatment, not a personal deadline for reaching a plateau. Ongoing review should consider response, tolerability and the treatment plan rather than promising accelerating loss every month. STEP 5 study
Ozempic vs. Wegovy Dosing Differences
Keep the product and indication attached to any dose comparison.
Wegovy Dosing (Weight Loss)
Oral schedules differ from this injection table; use formulation-specific instructions.
Ozempic Dosing (Diabetes)
Ozempic injection starts at 0.25 mg weekly for four weeks, then 0.5 mg—not a choice of either amount as the standard starting dose. Later increases depend on the indication; the maximum recommended injection dose is 2 mg weekly. Ozempic is not labeled for chronic weight management. Ozempic prescribing information
In STEP 2, 1,210 adults with type 2 diabetes were randomized to 2.4 mg, 1 mg or placebo with lifestyle intervention for 68 weeks. Average weight change was −9.6% with 2.4 mg versus −3.4% with placebo. Do not substitute the larger STEP 1 result from adults without diabetes as this population's expected outcome. STEP 2 study
Dose Adjustments and Special Situations
Slower Escalation
A delay can help make treatment more tolerable. The long-term outcome of a slower schedule depends on the person; a delay alone does not mean treatment has failed.
Staying at a Lower Dose
Discuss the exact product and indication before choosing ongoing treatment. A lower amount used in practice is not automatically a labeled maintenance option.
Dose Reduction
Review persistent symptoms with your clinician. A dose reduction may change both tolerability and treatment response; the balance needs reassessment.
Higher Doses and Label Conditions
Not every dose above 2.4 mg is now off-label: see the conditional 7.2 mg option above. Insurance coverage does not establish approval or determine an appropriate amount.
STEP UP studied 1,407 adults with obesity without diabetes for 72 weeks. Treatment-policy average weight change was −18.7% with 7.2 mg, −15.6% with 2.4 mg and −3.9% with placebo. Gastrointestinal events occurred in 70.8%, 61.2% and 42.8%; altered skin sensations in 22.9%, 6.0% and 0.5%, respectively. The additional average benefit comes with tolerability considerations, not a guarantee that a higher dose is best for everyone. STEP UP study
What If You're Not Losing Weight?
Bring your weight trend, treatment dates, medication list, nutrition concerns and side effects to a follow-up visit. Ask whether the current product and treatment plan remain appropriate; do not use an online pounds-per-month target to decide on an increase.
Nausea is not proof the medication is working, and its absence does not prove failure. The pooled STEP analysis found weight loss was largely independent of gastrointestinal adverse events. Pooled STEP gastrointestinal analysis
Related Dosing Guides
Semaglutide Dosing Chart provides a visual reference for all dose levels and escalation timelines.
Wegovy Dosing Schedule covers the official Novo Nordisk escalation protocol in detail.
Ozempic Dosing explains diabetes-specific dosing and how it differs from weight loss dosing.
Oral Semaglutide discusses formulations with different dosing and administration instructions from weekly injections.
Frequently Asked Questions
Frequently Asked Questions
For Wegovy injection, 0.25 mg once weekly for four weeks. Oral formulations use a different schedule.
Usually four-week steps, with delays for intolerance.
For adult Wegovy weight reduction: 1.7 or 2.4 mg weekly; see conditional escalation above.
Ask your clinician about symptoms and the product's missed-dose or restart instructions. Do not create a catch-up dose.
Yes. Ozempic injection has its own indication-specific schedule and a 2 mg weekly maximum; do not substitute Wegovy instructions.
Your prescriber can assess the conditional 7.2 mg option described above.
A prescriber can reassess treatment for intolerance. The appropriate maintenance or restart amount depends on the exact product and indication.
Final Thoughts
Use the schedule to understand your prescription, not to create one. Keep product-specific dosing, trial averages and your own response separate. A useful plan combines realistic expectations, appropriate follow-up and attention to tolerability.